Search Results for "activate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for activate. Results 961 to 970 of 1331 total matches.
Arformoterol (Brovana) for COPD
The Medical Letter on Drugs and Therapeutics • Jul 02, 2007 (Issue 1264)
-blind, doubledummy, placebo- and active-controlled trial. Clin Ther 2007; 29:
261.
4. JP Hanrahan et ...
Arformoterol tartrate (Brovana - Sepracor), a singleisomer, long-acting beta2-agonist, has been approved by the FDA as an inhalation solution for nebulization for treatment of bronchoconstriction pulmonary disease (COPD). Arformoterol is the (R,R)-enantiomer of formoterol (Foradil), which is available as a powder for inhalation and was recently also approved as a solution for nebulization (Perforomist - Dey; available fall 2007)
Clenpiq - A Low-Volume Sodium Picosulfate-Based Colonoscopy Preparation
The Medical Letter on Drugs and Therapeutics • May 21, 2018 (Issue 1547)
picosulfate is
a prodrug that is converted to its active metabolite
(BHPM) by colonic bacteria. BHPM acts ...
The FDA has approved Clenpiq (Ferring), a low-volume
oral solution that contains sodium picosulfate,
magnesium oxide, and anhydrous citric acid, for colon
cleansing prior to colonoscopy in adults. The ready-to-drink
solution contains the same ingredients as Prepopik,
which is supplied as a powder for reconstitution.
Choice of Contraceptives
The Medical Letter on Drugs and Therapeutics • May 15, 2023 (Issue 1676)
of estrogen and progestin in each active pill.
In multiphasic oral contraceptives, the dose of one
or both ...
Intrauterine devices (IUDs) and the etonogestrel
implant are the most effective reversible contraceptive
methods available. Hormonal oral contraceptives,
patches, rings, and injectables are also effective in
preventing pregnancy. When used alone, barrier and
behavioral methods generally have higher failure
rates than other methods (see Table 1). Selection of
a contraceptive method is usually based on patient-specific factors and personal preference
Med Lett Drugs Ther. 2023 May 15;65(1676):73-80 doi:10.58347/tml.2023.1676a | Show Introduction Hide Introduction
Drugs for Hypertension
The Medical Letter on Drugs and Therapeutics • May 27, 2024 (Issue 1703)
Sympathomimetic Activity
Acebutolol4 – generic 200, 400 mg caps 400-800 mg divided bid 49.20 Similar ...
American College of Cardiology/American Heart
Association (ACC/AHA) guidelines for treatment of
hypertension were last published in 2018. Treatment
of hypertensive urgencies and emergencies is not
discussed here.
Med Lett Drugs Ther. 2024 May 27;66(1703):81-8 doi:10.58347/tml.2024.1703a | Show Introduction Hide Introduction
Comparison Table: Some Oral Antiseizure Medications (online only)
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024 (Issue 1708)
, ataxia, withdrawal
symptoms, seizures
CYP2C19 inhibitors may
increase exposure to active
metabolite ...
View the Comparison Table: Some Oral Antiseizure Medications
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e133-40 doi:10.58347/tml.2024.1708b | Show Introduction Hide Introduction
Vasodilators For Congestive Heart Failure
The Medical Letter on Drugs and Therapeutics • Jan 29, 1988 (Issue 758)
also have arteriolar vasodilating activity. Controlled trials of isosorbide
in patients ...
Vasodilators are widely used for treatment of congestive heart failure (CHF) that has not responded adequately to diuretics and digitalis. Vasodilator drugs redistribute blood volume in patients with heart failure, lowering pressure and reducing volume in the failing left ventricle, which leads to increased cardiac output, decreased pulmonary capillary wedge pressure, and improved exercise tolerance. Since the last Medical Letter review of this subject (Volume 26, page 115, 1984), some additional data have become available.
Octreotide - A Synthetic Somatostatin
The Medical Letter on Drugs and Therapeutics • Jul 14, 1989 (Issue 796)
(vasoactive intestinal peptide-secreting
tumors).
ACTIVITY — Human somatostatin, a peptide with 14 amino ...
Octreotide acetate (Sandostatin - Sandoz), a synthetic octapeptide that mimics the actions of somatostatin, was recently approved by the US Food and Drug Administration for symptomatic treatment of patients with metastatic carcinoid or VIPomas (vasoactive intestinal peptide-secreting tumors).
Adjuvant Chemotherapy of Early Breast Cancer
The Medical Letter on Drugs and Therapeutics • May 18, 1990 (Issue 818)
activity of the tumor, for example, measured by DNA flow cytometry, or the concentration in the
tumor ...
The most important prognostic variable in early breast cancer is axillary lymph node involvement. Based on past experience, after 10 years about 70% of node-negative patients will be alive and apparently free of disease; about 30% will have relapsed or died. Patients with positive nodes may have a 30% to 60% relapse rate, depending on the number of positive nodes and other prognostic factors, such as the presence of estrogen receptors (IC Henderson et al, in VT DeVita, Jr et al, eds, Cancer: Principles and Practice of Oncology, 3rd ed, Philadelphia:Lippincott, 1989, p 1197). Which of...
Mifepristone (RU 486)
The Medical Letter on Drugs and Therapeutics • Dec 14, 1990 (Issue 833)
, 1986). The drug is extensively metabolized and excreted mainly in bile. Serum concentrations of active ...
Recent articles in the press have suggested that mifepristone (RU 486 - Roussel Uclaf) can effectively and safely induce an abortion. The drug is currently available only in France and China, but the manufacturer has also applied for a license in the United Kingdom. Mifepristone has been used on an investigational basis in the USA as an abortifacient and for treatment of Cushing's disease and breast cancer, but no manufacturer has applied to the US Food and Drug Administration for approval to market the drug in this country.
Flumazenil
The Medical Letter on Drugs and Therapeutics • Jul 10, 1992 (Issue 874)
for receptor sites in the central nervous system, but has little agonist
activity of its own (RN Brogden ...
Flumazenil (Mazicon - Roche), a benzodiazepine receptor antagonist, has been approved by the US Food and Drug Administration to reverse the sedative effects of benzodiazepines after anesthesia, sedation for brief surgical or diagnostic procedures, or after benzodiazepine overdosage. The drug does not antagonize opioids, non-benzodiazepine sedatives, or anesthetic drugs.